NYSE:CAHHealthcare
How Investors Are Reacting To Cardinal Health (CAH) Expanding Actinium-225 Capacity For Targeted Alpha Therapies
In early April 2026, Cardinal Health announced a major expansion of Actinium-225 production at its Center for Theranostics Advancement in Indianapolis, adding a high-capacity line to its Drug Master File to boost cGMP-compliant supply for investigational and future commercial targeted alpha therapies.
This enlarged Actinium-225 footprint, already supporting more than 15 clinical trials worldwide, deepens Cardinal Health’s role as a key radiopharmaceutical partner for oncology drug developers...